Chemomab Therapeutics Is Heating Up And Could See A Move Soon
Chemomab Therapeutics LTD. (NASDAQ: CMMB) shares are trading higher Friday as retail traders continue to push stocks higher.
A Technical Look At Novan’s Stock Amid 80% Spike
Novan Inc. (NASDAQ: NOVN) shares are trading higher Friday after the company reported that B-SIMPLE4 pivotal Phase 3 trial of SB206 achieved significance for the primary endpoint with no adverse events.
Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Crispr Therapeutics AG (NASDAQ:CRSP) have announced new data from Phase 1/2 clinical trials evaluating CTX001 in beta-thalassemia and…
BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To Imbruvica
BeiGene Ltd (NASDAQ:BGNE) revealed an interim analysis of the Phase 3 ALPINE trial evaluating Brukinsa (zanubrutinib) to Johnson & Johnson’s (NYSE:JNJ) Imbruvica (ibrutinib)…
AbbVie-Roche’s Venclexta Shows Progression-Free Survival Of 74% In CLL Patients After Three Years Treatment
Genentech, a unit of Roche Holdings AG (OTC:RHHBY), and its collaborating partner AbbVie Inc (NYSE:ABBV) have announced long-term follow-up data from two Phase 3…
Curis Shares Drop After Updated CA-4948 Data From Mid-Stage Blood Cancer Trial
Curis Inc (NASDAQ:CRIS) has announced updated data from its ongoing Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia…
Equillium’s Itolizumab Shows Rapid, Durable Responses In Graft-Versus-Host-Disease Patients
Equillium Inc (NASDAQ:EQ) has announced positive topline data from the Phase 1b EQUATE study evaluating itolizumab in first-line acute graft-versus-host-disease (aGVHD).…
Autolus Therapeutics’ CAR T Cell Achieves 100% Complete Remission In Indolent B Cell Non-Hodgkin Cohort
Autolus Therapeutics plc (NASDAQ:AUTL) has announced new data from AUTO1 (obecabtagene autoleucel, obe-cel) in relapsed / refractory (r/r) indolent B cell…
Mustang Bio’s CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial
Mustang Bio Inc (NASDAQ:MBIO) has updated interim data from the ongoing Phase 1/2 trial evaluating MB-106 for high-risk B-cell non-Hodgkin lymphomas…